Investigating a new approach to treat steroid-resistant asthma
Modulation of airway epithelial syndecan-1 in a preclinical model of steroid-resistant asthma
This study is looking at a protein called syndecan-1 to see how it influences inflammation in people with steroid-resistant asthma, with the hope of finding new treatment options that could help those who don’t respond well to regular steroid medications.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project ID | NIH-11138200 on NIH RePORTER |
What this research studies
This research focuses on understanding how syndecan-1, a protein found on airway epithelial cells, affects inflammation in steroid-resistant asthma. The study will explore the role of this protein in regulating immune responses and how its cleavage can lead to increased inflammation. By using a preclinical model of asthma, researchers aim to identify potential therapeutic targets, including specific inhibitors that could reduce inflammation and improve airway function. Patients may benefit from insights gained about new treatment options that could be more effective for those who do not respond to standard steroid therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with severe allergic asthma who do not respond to steroid treatments.
Not a fit: Patients with mild asthma or those who respond well to standard steroid therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients suffering from steroid-resistant asthma, improving their quality of life.
How similar studies have performed: Other research has shown promising results with similar approaches targeting inflammatory pathways in asthma, suggesting potential for success in this area.
Where this research is happening
Burlington, United States
- University of Vermont & St Agric College — Burlington, United States (Active)
Researchers
- Principal investigator: Poynter, Matthew E — University of Vermont & St Agric College
- Study coordinator: Poynter, Matthew E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.